Company News-Bio-Thera Solutions, Ltd.

Bio-Thera Solutions’ Golimumab Biosimilars Receive FDA Approval as First Biosimilars to Simponi® and Simponi Aria®; Accord BioPharma to Commercialize IMMGOLIS™ (golimumab-sldi) and IMMGOLIS INTRI™ (golimumab-sldi) in the United States

2026-05-18

GUANGZHOU, China --- Bio-Thera Solutions (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline...

查看详情

12-022022

Bio-Thera Solutions Announces BAT8006 (Folate-Receptor-α-ADC) and BAT8008 (Trop2-ADC) Poster Presentations at the 2022 San Antonio Breast Cancer Symposium

Guangzhou, China --(BUSINESS WIRE)--Bio-Thera Solutions, a commercial-stage biopharmaceutical company developing apipeli...
11-012022

Bio-Thera Solutions Initiates Phase III Clinical Trial for BAT2306, a Proposed Biosimilar of Cosentyx® (Secukinumab)

Guangzhou, China --(BUSINESSWIRE)--Bio-Thera Solutions, Ltd. (688177.SH), a commercial-stage pharmaceuticalcompany, toda...
10-152022

Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT2606, a Proposed Biosimilar of Nucala® (mepolizumab)

Guangzhou, China --(BUSINESSWIRE)-- Bio-TheraSolutions, Ltd. (SH: 688177),a commercial-stage biopharmaceutical company, ...

上一页 ···17 18 19 20 21 ··· 下一页